Skip to main content
. 2026 Oct 1;13:1950636. doi: 10.3389/fmed.2026.1950636

Figure 2.

Four line graphs display tumor marker trends (CA125, CA15-3, CYFRA21-1, NSE) from April 2025 to March 2026, showing sharp increases above upper normal limits by early 2026. Below, a timeline details clinical events, treatments, disease progression, and death over the same period.

Tumor marker trends and clinical timeline. Panel A shows changes in CA125, CA15-3, CYFRA21-1, and NSE during the disease course. Panel B summarizes the main diagnostic, therapeutic, progression, and outcome events.